This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ocera Therapeutics Inc.
Drug Names(s): TZP-101
Description: TZP-101 is a small molecule ghrelin receptor agonist, given intravenously. Ghrelin is a peptide hormone known to stimulate both gastrointestinal motility and growth hormone release.
Deal Structure: Ulimorelin was originally developed by Tranzyme.
In June 2010, Tranzyme Pharma and Norgine entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize ulimorelin (TZP-101) in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Under the agreement, Norgine will make an upfront payment of $8 million and will also make an equity investment in Tranzyme. Further, Tranzyme is eligible to receive up to approximately $150 million if certain development, regulatory and commercial milestones are achieved. Tranzyme will also receive escalating double-digit royalties on net sales in the licensed territories. The companies will jointly fund further development of ulimorelin.
Partners: Norgine B.V.
Additional information available to subscribers only: